Pourheydar Maryam, Hasanzadeh Shapour, Razi Mazdak, Pourheydar Bagher, Najafi Gholamreza
Department of Basic Sciences, Faculty of Veterinary Medicine, Urmia University, Urmia, Iran.
Department of Anatomical Sciences, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran.
Vet Res Forum. 2021 Winter;12(1):109-116. doi: 10.30466/vrf.2019.96822.2315. Epub 2021 Mar 15.
The current study was conducted to analyze the dose-dependent effects of liraglutide against the diabetes-induced detrimental impact on sperm parameters and fertilization potential. For this purpose, 42 adult male mice were randomly divided into control (with no intervention) and experimental groups. Next, the experimental group was subdivided into diabetic, 1.20 mg kg liraglutide-received diabetic, 1.80 mg kg liraglutide-received diabetic, 1.20 mg kg liraglutide-received non-diabetic and 1.80 mg kg liraglutide-received non-diabetic groups. All chemicals were administrated subcutaneously. Following 42 days, the animals were euthanized, and sperm samples were collected. The sperm count, motility, viability, DNA integrity, and maturity were analyzed and compared between groups. Moreover, the sperm fertilization potential was investigated by fertilization (IVF). For this purpose, the preimplantation embryo development at 2-cell, 4-cell, morula, and blastocyst stages was investigated and compared. Observations revealed that diabetes significantly diminished sperm count, motility, viability, chromatin condensation, and DNA integrity percentages a control group. On the other hand, 1.20 mg kg and 1.80 mg kg of liraglutide did not improve sperm motility and viability, while ameliorated sperm count and chromatin condensation and DNA integrity in diabetic animals. The diabetic animals represented diminished preimplantation embryo development, which was not altered in liraglutide-received groups. In conclusion, at least in administrated doses, liraglutide could not improve the sperm viability and motility and, via this mechanism, could not induce an appropriate/beneficial effect on IVF outcome.
本研究旨在分析利拉鲁肽的剂量依赖性效应，以对抗糖尿病对精子参数和受精潜能产生的有害影响。为此，将42只成年雄性小鼠随机分为对照组（无干预）和实验组。接下来，将实验组再细分为糖尿病组、接受1.20 mg/kg利拉鲁肽的糖尿病组、接受1.80 mg/kg利拉鲁肽的糖尿病组、接受1.20 mg/kg利拉鲁肽的非糖尿病组和接受1.80 mg/kg利拉鲁肽的非糖尿病组。所有化学物质均通过皮下注射给药。42天后，对动物实施安乐死并采集精子样本。分析并比较了各组之间的精子计数、活力、存活率、DNA完整性和成熟度。此外，通过体外受精（IVF）研究了精子的受精潜能。为此，研究并比较了2细胞、4细胞、桑葚胚和囊胚阶段的植入前胚胎发育情况。观察结果显示，糖尿病显著降低了精子计数、活力、存活率、染色质凝聚和DNA完整性百分比，与对照组相比有差异。另一方面，1.20 mg/kg和1.80 mg/kg的利拉鲁肽并未改善精子活力和存活率，但改善了糖尿病动物的精子计数、染色质凝聚和DNA完整性。糖尿病动物的植入前胚胎发育减少，而接受利拉鲁肽的组中这一情况并未改变。总之，至少在所使用的剂量下，利拉鲁肽无法改善精子存活率和活力，因此无法通过这种机制对体外受精结果产生适当/有益的影响。
